Skip to main content
Conference Highlights ASH
A Multicenter, Phase 4 Observational Study of Ofatumumab in Chronic Lymphocytic Leukemia: A European Research Initiative on CLL (ERIC) Study
Read More
Conference Highlights ASH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib and Rituximab for Previously Treated Patients with Chronic Lymphocytic Leukemia
Read More
Conference Highlights ASH
Chemoimmunotherapy with Fludarabine, Cyclophosphamide, and Rituximab versus Bendamustine and Rituximab in Previously Untreated and Physically Fit Patients with Advanced Chronic Lymphocytic Leukemia
Read More
Conference Highlights ASH
Chronic Lymphocytic Leukemia: A New Treatment Era is Born
Read More
Conference Highlights ASH
Combination Biologic Therapy Without Chemotherapy as Initial Treatment for Mantle-Cell Lymphoma: Multicenter Phase 2 Study of Lenalidomide Plus Rituximab
Read More
Conference Highlights ASH
Head-To-Head Comparison of Obinutuzumab Plus Chlorambucil versus Rituximab Plus Chlorambucil in Patients with Chronic Lymphocytic Leukemia and Coexisting Medical Conditions: Final Stage 2 Results of the CLL11 Trial
Read More
Conference Highlights ASH
Ibrutinib in Combination with Bendamustine and Rituximab Is Active and Tolerable in Patients with Relapsed or Refractory CLL/SLL: Final Results of a Phase 1b Study
Read More
Conference Highlights ASH
Ibrutinib in Combination with Rituximab is Well Tolerated and Induces a High Rate of Durable Remissions in Patients with High-Risk Chronic Lymphocytic Leukemia: New, Updated Results of a Phase 2 Trial in 40 Patients
Read More
Conference Highlights ASH
Ibrutinib Overcomes Carfilzomib Resistance in Immunoproteasome-Deficient Mantle-Cell Lymphoma
Read More
Conference Highlights ASH
Lenalidomide, Bendamustine, and Rituximab as First-Line Therapy for Patients >65 Years with Mantle-Cell Lymphoma: Preliminary Results from the Nordic Lymphoma Group MCL4 (LENA-BERIT) Phase 1-2 Trial
Read More
Page 1 of 3
Results 1 - 10 of 22